Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Development and validation of a reverse phase HPLC method for SHetA2, a novel anti-cancer drug, in mouse biological samples.

Kukut Hatipoglu M, Mahjabeen S, Garcia-Contreras L.

J Pharm Biomed Anal. 2019 Jun 5;170:124-131. doi: 10.1016/j.jpba.2019.03.037. Epub 2019 Mar 18.

PMID:
30921646
2.

Cryogenic Fabrication of Dry Powders to Enhance the Solubility of a Promising Anticancer Drug, SHetA2, for Oral Administration.

Ibrahim M, Hatipoglu MK, Garcia-Contreras L.

AAPS PharmSciTech. 2019 Jan 2;20(1):20. doi: 10.1208/s12249-018-1204-z.

PMID:
30604109
3.

Pharmacokinetics and Pharmacodynamics of Escalating Doses of SHetA2 After Vaginal Administration to Mice.

Mahjabeen S, Hatipoglu MK, Benbrook DM, Garcia-Contreras L.

J Pharm Sci. 2018 Dec;107(12):3179-3186. doi: 10.1016/j.xphs.2018.08.024. Epub 2018 Sep 6.

PMID:
30196041
4.

Pharmacokinetics and pharmacodynamics of high doses of inhaled dry powder drugs.

Kukut Hatipoglu M, Hickey AJ, Garcia-Contreras L.

Int J Pharm. 2018 Oct 5;549(1-2):306-316. doi: 10.1016/j.ijpharm.2018.07.050. Epub 2018 Aug 2. Review.

PMID:
30077761
5.

Influence of the estrus cycle of the mouse on the disposition of SHetA2 after vaginal administration.

Mahjabeen S, Hatipoglu MK, Benbrook DM, Kosanke SD, Garcia-Contreras D, Garcia-Contreras L.

Eur J Pharm Biopharm. 2018 Sep;130:272-280. doi: 10.1016/j.ejpb.2018.07.004. Epub 2018 Jul 4.

6.

Development of a dietary formulation of the SHetA2 chemoprevention drug for mice.

Benbrook DM, Janakiram NB, Chandra V, Pathuri G, Madka V, Stratton NC, Masamha CP, Farnsworth CN, Garcia-Contreras L, Hatipoglu MK, Lighfoot S, Rao CV.

Invest New Drugs. 2018 Aug;36(4):561-570. doi: 10.1007/s10637-017-0550-0. Epub 2017 Dec 22.

7.

SHetA2 Dry Powder Aerosols for Tuberculosis: Formulation, Design, and Optimization Using Quality by Design.

Ibrahim M, Hatipoglu MK, Garcia-Contreras L.

Mol Pharm. 2018 Jan 2;15(1):300-313. doi: 10.1021/acs.molpharmaceut.7b01062. Epub 2017 Dec 18.

PMID:
29219321
8.

Optimization of a Vaginal Suppository Formulation to Deliver SHetA2 as a Novel Treatment for Cervical Dysplasia.

Mahjabeen S, Hatipoglu MK, Chandra V, Benbrook DM, Garcia-Contreras L.

J Pharm Sci. 2018 Feb;107(2):638-646. doi: 10.1016/j.xphs.2017.09.018. Epub 2017 Oct 6.

9.

Double-balloon enteroscopy: Indications, approaches, diagnostic and therapeutic yield, and safety. Early experience at a single center.

García-Correa JJE, Ramírez-García JJ, García-Contreras LF, Fuentes-Orozco C, Irusteta-Jiménez L, Michel-Espinoza LR, Carballo Uribe AS, Torres Chávez JA, González-Ojeda A.

Rev Gastroenterol Mex. 2018 Jan - Mar;83(1):31-40. doi: 10.1016/j.rgmx.2017.04.001. Epub 2017 May 12. English, Spanish.

10.

Pharmacokinetics of Ethionamide Delivered in Spray-Dried Microparticles to the Lungs of Guinea Pigs.

Garcia-Contreras L, Padilla-Carlin DJ, Sung J, VerBerkmoes J, Muttil P, Elbert K, Peloquin C, Edwards D, Hickey A.

J Pharm Sci. 2017 Jan;106(1):331-337. doi: 10.1016/j.xphs.2016.09.033. Epub 2016 Nov 11.

11.

Inhaled Formulation Design for the Treatment of Lung Infections.

Garcia-Contreras L, Yadav KS.

Curr Pharm Des. 2015;21(27):3875-901. Review.

PMID:
26290199
12.

Pharmacokinetics of Inhaled Rifampicin Porous Particles for Tuberculosis Treatment: Insight into Rifampicin Absorption from the Lungs of Guinea Pigs.

Garcia Contreras L, Sung J, Ibrahim M, Elbert K, Edwards D, Hickey A.

Mol Pharm. 2015 Aug 3;12(8):2642-50. doi: 10.1021/acs.molpharmaceut.5b00046. Epub 2015 May 26.

PMID:
25942002
13.

Inhalation drug delivery devices: technology update.

Ibrahim M, Verma R, Garcia-Contreras L.

Med Devices (Auckl). 2015 Feb 12;8:131-9. doi: 10.2147/MDER.S48888. eCollection 2015. Review.

14.

Liquid chromatographic determination of CPZEN-45, a novel anti-tubercular drug, in biological samples.

Hanif SN, Hickey AJ, Garcia-Contreras L.

J Pharm Biomed Anal. 2014 Jan;88:370-6. doi: 10.1016/j.jpba.2013.09.014. Epub 2013 Oct 6.

15.

Mechanisms of absorption and elimination of drugs administered by inhalation.

Ibrahim M, Garcia-Contreras L.

Ther Deliv. 2013 Aug;4(8):1027-45. doi: 10.4155/tde.13.67. Review.

PMID:
23919477
16.

Implications of increased nanoparticle absorption by infant lungs: future prospects.

Garcia-Contreras L, Ibrahim M.

Ther Deliv. 2013 Apr;4(4):417-20. doi: 10.4155/tde.13.1. No abstract available.

17.

Pharmaceutical aerosols for the treatment and prevention of tuberculosis.

Hanif SN, Garcia-Contreras L.

Front Cell Infect Microbiol. 2012 Sep 7;2:118. doi: 10.3389/fcimb.2012.00118. eCollection 2012. Review.

18.

Pharmacokinetics of sequential doses of capreomycin powder for inhalation in guinea pigs.

Garcia-Contreras L, Muttil P, Fallon JK, Kabadi M, Gerety R, Hickey AJ.

Antimicrob Agents Chemother. 2012 May;56(5):2612-8. doi: 10.1128/AAC.06145-11. Epub 2012 Feb 13.

19.

Isoxyl assays in plasma.

Wang C, Garcia-Contreras L, Muttil P, Hickey AJ.

J Pharm Biomed Anal. 2012 Feb 23;60:1-6. doi: 10.1016/j.jpba.2011.10.029. Epub 2011 Nov 4.

PMID:
22119164
20.

Pulmonary immunization of guinea pigs with diphtheria CRM-197 antigen as nanoparticle aggregate dry powders enhance local and systemic immune responses.

Muttil P, Pulliam B, Garcia-Contreras L, Fallon JK, Wang C, Hickey AJ, Edwards DA.

AAPS J. 2010 Dec;12(4):699-707. doi: 10.1208/s12248-010-9229-6. Epub 2010 Sep 28.

21.

Pulmonary immunization using antigen 85-B polymeric microparticles to boost tuberculosis immunity.

Lu D, Garcia-Contreras L, Muttil P, Padilla D, Xu D, Liu J, Braunstein M, McMurray DN, Hickey AJ.

AAPS J. 2010 Sep;12(3):338-47. doi: 10.1208/s12248-010-9193-1. Epub 2010 Apr 27.

22.

Immunization of guinea pigs with novel hepatitis B antigen as nanoparticle aggregate powders administered by the pulmonary route.

Muttil P, Prego C, Garcia-Contreras L, Pulliam B, Fallon JK, Wang C, Hickey AJ, Edwards D.

AAPS J. 2010 Sep;12(3):330-7. doi: 10.1208/s12248-010-9192-2. Epub 2010 Apr 24.

23.

Dry powder PA-824 aerosols for treatment of tuberculosis in guinea pigs.

Garcia-Contreras L, Sung JC, Muttil P, Padilla D, Telko M, Verberkmoes JL, Elbert KJ, Hickey AJ, Edwards DA.

Antimicrob Agents Chemother. 2010 Apr;54(4):1436-42. doi: 10.1128/AAC.01471-09. Epub 2010 Jan 19.

24.

Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery.

Sung JC, Padilla DJ, Garcia-Contreras L, Verberkmoes JL, Durbin D, Peloquin CA, Elbert KJ, Hickey AJ, Edwards DA.

Pharm Res. 2009 Aug;26(8):1847-55. doi: 10.1007/s11095-009-9894-2. Epub 2009 Apr 30.

PMID:
19407933
25.

Screening for potential adjuvants administered by the pulmonary route for tuberculosis vaccines.

Wang C, Muttil P, Lu D, Beltran-Torres AA, Garcia-Contreras L, Hickey AJ.

AAPS J. 2009 Mar;11(1):139-47. doi: 10.1208/s12248-009-9089-0. Epub 2009 Mar 10.

26.

Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation.

Sung JC, Garcia-Contreras L, Verberkmoes JL, Peloquin CA, Elbert KJ, Hickey AJ, Edwards DA.

Antimicrob Agents Chemother. 2009 Apr;53(4):1338-43. doi: 10.1128/AAC.01389-08. Epub 2009 Jan 12.

27.

Immunization by a bacterial aerosol.

Garcia-Contreras L, Wong YL, Muttil P, Padilla D, Sadoff J, Derousse J, Germishuizen WA, Goonesekera S, Elbert K, Bloom BR, Miller R, Fourie PB, Hickey A, Edwards D.

Proc Natl Acad Sci U S A. 2008 Mar 25;105(12):4656-60. doi: 10.1073/pnas.0800043105. Epub 2008 Mar 14.

28.

In vivo animal models for drug delivery across the lung mucosal barrier.

Cryan SA, Sivadas N, Garcia-Contreras L.

Adv Drug Deliv Rev. 2007 Sep 30;59(11):1133-51. Epub 2007 Aug 31. Review. Erratum in: Adv Drug Deliv Rev. 2008 Apr 29;60(7):858.

PMID:
17900750
29.

Poly (lactide-co-glycolide) microspheres in respirable sizes enhance an in vitro T cell response to recombinant Mycobacterium tuberculosis antigen 85B.

Lu D, Garcia-Contreras L, Xu D, Kurtz SL, Liu J, Braunstein M, McMurray DN, Hickey AJ.

Pharm Res. 2007 Oct;24(10):1834-43. Epub 2007 Jul 27.

PMID:
17657598
30.

Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin.

Fiegel J, Garcia-Contreras L, Thomas M, VerBerkmoes J, Elbert K, Hickey A, Edwards D.

Pharm Res. 2008 Apr;25(4):805-11. Epub 2007 Jul 27.

PMID:
17657592
31.

Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model.

Garcia-Contreras L, Fiegel J, Telko MJ, Elbert K, Hawi A, Thomas M, VerBerkmoes J, Germishuizen WA, Fourie PB, Hickey AJ, Edwards D.

Antimicrob Agents Chemother. 2007 Aug;51(8):2830-6. Epub 2007 May 21.

32.

Evaluation of dosing regimen of respirable rifampicin biodegradable microspheres in the treatment of tuberculosis in the guinea pig.

Garcia-Contreras L, Sethuraman V, Kazantseva M, Godfrey V, Hickey AJ.

J Antimicrob Chemother. 2006 Nov;58(5):980-6. Epub 2006 Sep 13.

PMID:
16971416
33.

Aerosol treatment of cystic fibrosis.

Garcia-Contreras L, Hickey AJ.

Crit Rev Ther Drug Carrier Syst. 2003;20(5):317-56. Review.

PMID:
14959788
34.

Evaluation of novel particles as pulmonary delivery systems for insulin in rats.

Garcia-Contreras L, Morçöl T, Bell SJ, Hickey AJ.

AAPS PharmSci. 2003;5(2):E9.

35.

Pharmaceutical and biotechnological aerosols for cystic fibrosis therapy.

Garcia-Contreras L, Hickey AJ.

Adv Drug Deliv Rev. 2002 Dec 5;54(11):1491-504. Review.

PMID:
12458157
36.

Immediate and short-term cellular and biochemical responses to pulmonary single-dose studies of insulin and H-MAP.

Garcia-Contreras L, Sarubbi D, Flanders E, O'Toole D, Smart J, Newcomer C, Hicke AJ.

Pharm Res. 2001 Dec;18(12):1685-93.

PMID:
11785687
37.

Facilitation of pulmonary insulin absorption by H-MAP: pharmacokinetics and pharmacodynamics in rats.

Suarez S, Garcia-Contreras L, Sarubbi D, Flanders E, O'Toole D, Smart J, Hickey AJ.

Pharm Res. 2001 Dec;18(12):1677-84.

PMID:
11785686
38.
39.

Biodegradable cisplatin microspheres for direct brain injection: preparation and characterization.

García-Contreras L, Abu-Izza K, Lu DR.

Pharm Dev Technol. 1997 Feb;2(1):53-65.

PMID:
9552431
40.

Supplemental Content

Loading ...
Support Center